LeonaBio, Inc. Reports Q2 2026 Financial Results

What Happened

• On August 14, 2026, LeonaBio, Inc. announced and furnished a press release reporting its financial results for the quarter ended June 30, 2026 (press release furnished as Exhibit 99.1 to the Form 8-K). The Form 8-K was signed by President and CEO Mark Litton.
• The filing itself furnishes the press release; it does not include the detailed financial figures in the 8‑K text. Investors should review the press release on the company’s investor site or other channels for the full results.

Key Details

• Date of filing and press release: August 14, 2026.
• Reporting period: Quarter ended June 30, 2026.
• Exhibit furnished: Exhibit 99.1 — LeonaBio press release (financial results).
• Regulation FD disclosure channels listed: SEC filings, press releases, conference calls, company website (www.leonabio.com), investor site (investors.leonabio.com), and social media (X/@leonabioinc, LinkedIn, Instagram, Facebook).

Why It Matters

• This 8-K signals LeonaBio has released its latest quarterly results; those results (revenue, net loss/profit, cash position, and any commentary on clinical or operational milestones) could affect the stock and investor decisions.
• Retail investors should read the furnished press release and company investor materials for the specific numbers and management commentary. Note that the company states the press release is furnished (not “filed”) under the Exchange Act, which affects how it may be incorporated by reference in other filings.